Towards the Development of a Targeted Albumin-Binding Radioligand for Theranostic Applications: Synthesis, Radiolabelling and Preliminary In Vivo Studies
Preprint
- 22 July 2020
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
GluCAB is a newly synthesised macrocyclic radioligand designed to bind in vivo to albumin (HSA) for the purpose of development as a dual-targeting oncological theranostic agent. Subsequent to its synthesis and 64 Cu-radiolabelling, this radioligand has show a prolonged circulation time in healthy mice but with appropriate systemic clearance within 24 h. This radioligand meets the criteria to be further investigated for tumour targeting and uptake.Keywords
All Related Versions
- Published version: Nuclear Medicine and Biology, 94-95, 53.